AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 42 min read$PDEX

Pro-Dex Jumps On Higher Q4 Earnings And Revenue Growth

Pro-Dex Inc. (PDEX) reported Q4 2026 revenue growth of 17% to $20.41M and net income growth of 140% to $2.86M. Full-year revenue rose 16% to $77.55M, with net income up 52% to $13.66M. Shares surged over 16% following the earnings release.

Original reporting
rttnews.com
Published Sep 4, 2026, 3:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 4:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PDEX
Bullish
high confidence
Mentioned
$PDEX
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$PDEXBullishHigh
01

Why it matters

Earnings beat drives a 16% intraday rally, suggesting short‑term buying interest.

02

Market read

First‑report earnings with strong growth and a notable price move make this a high‑value trading story.

03

What to watch

Potential supply‑chain constraints for battery‑powered instruments.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

Pro‑Dex Inc. reports its Q4 and FY 2026 financials, highlighting revenue growth and profit expansion.

Company-level read

Ticker impact

$PDEXBullishHigh confidence
Context

Q4 earnings and full-year results posted, revenue up 17% YoY and net income up, driving a 16% share jump.

Expected impact

Potential continued rally toward recent highs if momentum persists.

Evidence & confidence

First‑report earnings with double‑digit revenue growth and a sizable same‑day price jump indicate fresh, actionable information.

Market effects

Sector

Positive signal for medical device and surgical instrument sector.

Regional

U.S. biotech/medical device stocks may see modest lift.

Global

Limited to niche medical device space.

Counterpoint

What could challenge this read

Valuation may already price in growth; watch for margin pressure.

Key entities

  • Company
    Pro‑Dex Inc.

    Developer and manufacturer of powered surgical instruments.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 3
$PDEXMed

PRO DEX INC (PDEX): Results of Operations and Financial Condition

PRO DEX INC (PDEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Richard L. Van Kirk, Chief Executive Officer (949) 769-3200 For Immediate Release PRO-DEX, INC. ANNOUNCES FISCAL 2026 FOURTH QUARTER AND FULL-YEAR RESULTS IRVINE, CA, September 3, 2026 - PRO-DEX, INC. (NasdaqCM: PDEX) t oday announced financial results for i

SEC EDGAR 8-K2 min
SEP 28
HighAI 8/10

TotalEnergies Targets $10 Billion Cash Flow Gain by 2030

TotalEnergies aims to boost oil, gas, and electricity production by 4% annually through 2030, adding $10 billion in free cash flow by 2030. The company expects oil and gas production to rise over 3% annually, while electricity generation grows over 20% annually, reaching 100-120 TWh by 2030. TotalEnergies plans to invest $14-17 billion annually from 2027-2032 and increase dividends by over 5% annually from 2026-2030.

finance.yahoo.com3 min
SEP 28
$TTEMed

Why Is TotalEnergies Stock Falling Monday? - TotalEnergies (NYSE:TTE)

TotalEnergies (TTE) stock rose 2% premarket after reaffirming long-term growth targets, including 3%+ annual oil/gas production growth and 4% overall energy production growth through 2030. The company aims for 50% reduction in Scope 1/2 emissions and 80% methane reduction by 2030. It plans $14B-$17B annual investments from 2027-2032, 5%+ dividend growth, and $2.5B-$2.5B share buybacks in 2026-2027. Analysts have mixed views; TTE trades at $92.40, with a Buy consensus and $97.67 avg.

benzinga.com2 min
SEP 28
$RIVNMed

Is Rivian Stock Riskier Than It Looks?

Rivian (RIVN) trades at 3.5x revenue, higher than the S&P 500's 3.1x. The company lost $3.2B over the past year. Management warns that the R2 SUV launch, crucial for growth, could face delays due to supplier issues. Q2 2026 deliveries beat expectations, but car revenue fell 14.6% YoY. Gross loss narrowed to $36M in Q2 2026, but the R2 ramp added $100M in extra costs. Shares are down 31% from their 52-week high.

finance.yahoo.com2 min